Compare · DNTH vs NVO
DNTH vs NVO
Side-by-side comparison of Dianthus Therapeutics Inc. (DNTH) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DNTH and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 41.7x DNTH ($4.17B).
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for DNTH).
- NVO has more recent analyst coverage (25 ratings vs 16 for DNTH).
- Company
- Dianthus Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $72.16-3.08%
- $38.82-1.05%
- Market cap
- $4.17B
- $173.66B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2018
- News (4w)
- 3
- 4
- Recent ratings
- 16
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest DNTH
- Dianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharma
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2026 AANEM Annual Meeting
- CHIEF ACCOUNTING OFFICER Carr Edward exercised 20,000 shares at a strike of $17.88 and sold $2,027,646 worth of shares (20,000 units at $101.38) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-3ASR filed by Dianthus Therapeutics Inc.
- SEC Form 144 filed by Dianthus Therapeutics Inc.
- Analyst initiated coverage on Dianthus Therapeutics with a new price target
- Citigroup initiated coverage on Dianthus Therapeutics with a new price target
- EVP, Head of R&D Randhawa Simrat exercised 23,124 shares at a strike of $20.63 and sold $2,460,690 worth of shares (23,124 units at $106.41) as part of a pre-agreed trading plan (SEC Form 4)
- Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank